









Markets
/
Stocks
/
nasdaq-prct
/

Procept Biorobotics Corp

PRCT

34.380USD

-1.550-4.31%

Close 10/30, 16:00（ET）Quotes delayed by 15 min

1.91BMarket Cap

LossP/E TTM



Procept Biorobotics Corp

34.380

-1.550-4.31%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Procept Biorobotics Corp

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Procept Biorobotics Corp's Score

Industry at a Glance

Industry Ranking

13 / 210

Overall Ranking

65 / 4623

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

65.182

Target Price

+76.41%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Procept Biorobotics Corp Highlights

StrengthsRisks

PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 199.27% year-on-year.

Fairly Valued

The company’s latest PE is -23.16, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 54.59M shares, decreasing 2.13% quarter-over-quarter.

Held by Wasatch Global Investors

Star Investor Wasatch Global Investors holds 188.69K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.66.

Financial Health

Currency: USD Updated: 2025-10-29

The company's current financial score is 8.58, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 79.18M, representing a year-over-year increase of 48.41%, while its net profit experienced a year-over-year increase of 23.60%.

Score

Industry at a Glance

Previous score

8.58

Change



Financials

9.85

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.64

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

9.41

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.60

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.40

Key Metrics

Free cash flow

No Data

Procept Biorobotics Corp's Company Valuation

Currency: USD Updated: 2025-10-29

The company’s current valuation score is 7.41, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -23.16, which is -53.87% below the recent high of -10.68 and -120.34% above the recent low of -51.02.

Score

Industry at a Glance

Previous score

7.41

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 13/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-29

The company’s current earnings forecast score is 8.46, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Procept Biorobotics Corp is 62.00, with a high of 85.00 and a low of 50.00.

Score

Industry at a Glance

Previous score

8.46

Change

Support & Resistance

No Data

Analyst Rating

Based on 13 analysts

Buy

Current Rating

65.182

Target Price

+81.41%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

110

Total

Median

Average

Company name

Ratings

Analysts

Procept Biorobotics Corp

PRCT

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-29

The company’s current price momentum score is 8.42, which is higher than the Healthcare Equipment & Supplies industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 38.10 and the support level at 32.93, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.58

Change

-0.16

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.740

Neutral

RSI(14)

43.941

Neutral

STOCH(KDJ)(9,3,3)

53.481

Sell

ATR(14)

1.735

High Vlolatility

CCI(14)

17.444

Neutral

Williams %R

56.094

Sell

TRIX(12,20)

-0.180

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

35.720

Sell

MA10

35.062

Sell

MA20

34.678

Sell

MA50

36.887

Sell

MA100

45.218

Sell

MA200

53.028

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-29

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.43. The latest institutional shareholding proportion is 98.11%, representing a quarter-over-quarter decrease of 2.08%. The largest institutional shareholder is The Vanguard, holding a total of 5.24M shares, representing 9.41% of shares outstanding, with 0.79% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

7.70M

-5.13%

The Vanguard Group, Inc.

Star Investors

5.24M

+2.36%

BlackRock Institutional Trust Company, N.A.

3.73M

+8.09%

AllianceBernstein L.P.

2.16M

+0.61%

Westfield Capital Management Company, L.P.

1.60M

+113.52%

T. Rowe Price Investment Management, Inc.

1.53M

+7.94%

Geode Capital Management, L.L.C.

1.30M

+9.73%

T. Rowe Price Associates, Inc.

Star Investors

1.27M

+25.63%

State Street Investment Management (US)

1.27M

+6.89%

Risk Assessment

Currency: USD Updated: 2025-10-29

The company’s current risk assessment score is 4.96, which is higher than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.99. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.